Clinical Trial Update: Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the efficacy and safety of ON 01910.Na in patients with myelodysplastic syndrome, including those with trisomy 8 or higher-ris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndrome

Drugs mentioned

• ON-01910.Na (ON-01910 sodium)

Snippet

Sponsor: Traws Pharma, Inc. | Conditions: Myelodysplastic Syndrome | Phase 2 | Status: COMPLETED